Biography and Research Information
OverviewAI-generated summary
Liyan Mazahreh's research focuses on the clinical outcomes and treatment strategies for various medical conditions. Mazahreh has investigated the risk of infections associated with bispecific antibodies in patients with multiple myeloma, contributing to a deeper understanding of treatment-related adverse events in this patient population. Further research has explored the duration of immune checkpoint inhibitors in oncology, examining whether longer treatment periods are always more beneficial. Additionally, Mazahreh's work includes studies on the severity of asthma exacerbations in children during periods of non-pharmaceutical interventions, as well as investigations into eosinophilic chronic rhinosinusitis. Mazahreh collaborates with researchers at the University of Arkansas for Medical Sciences, including Farah Mazahreh, A. Mazin Safar, Fenghuang Zhan, and Sharmilan Thanendrarajan, with whom multiple shared publications have been produced.
Metrics
- h-index: 2
- Publications: 14
- Citations: 142
Selected Publications
-
Hospitalizations and Severity of Rhinovirus-Associated Asthma Exacerbations in Children During the Institution of Non-pharmaceutical Interventions (2026)
-
Exploring new frontiers in eosinophilic chronic rhinosinusitis (2025)
-
Abstract 3214: The duration of immune checkpoint inhibitors (ICI) in oncology: Longer is not better (2025)
-
Ongoing Radiographic Response for Over 20 Months in Metastatic Cancer Without Continued Immune Checkpoint Inhibitor (ICI) Dosing (2025)
-
Tumor Response to Immune-Oncology Therapy Despite High-Dose Steroid Intervention in a Patient With Papillary Renal Cell Carcinoma and Immune-Related Myasthenia Gravis (2025)
-
Abstract 1177: The chronology of immune-related adverse events (irAEs)-mechanistic implications (2024)
Collaboration Network
Top Collaborators
Farah Mazahreh
University of Arkansas for Medical Sciences
8 shared publications
In database
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Risk of Infections Associated with the Use of Bispecific Antibodies in Multiple Myeloma: A Pooled Analysis
- Tumor Response to Immune-Oncology Therapy Despite High-Dose Steroid Intervention in a Patient With Papillary Renal Cell Carcinoma and Immune-Related Myasthenia Gravis
- Abstract 4385: Unprecedented tumor: immune interaction–clinical and drug-development implications
- Weight loss (WL) as a predictive factor for immune oncology (IO).
Showing 5 of 8 shared publications
A. Mazin Safar
University of Arkansas for Medical Sciences (US)
4 shared publications
- Weight loss (WL) as a predictive factor for immune oncology (IO).
- Abstract 1177: The chronology of immune-related adverse events (irAEs)-mechanistic implications
- 512LBA (PB-512) LBA Posters: Off-the-Shelf Therapeutic Overactivation (TOA): A plea we can’t refuse!
- Abstract 3214: The duration of immune checkpoint inhibitors (ICI) in oncology: Longer is not better
Carolina Schinke
Winthrop Rockefeller Foundation
2 shared publications
In database
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Risk of Infections Associated with the Use of Bispecific Antibodies in Multiple Myeloma: A Pooled Analysis
Sharmilan Thanendrarajan
Winthrop Rockefeller Foundation
2 shared publications
In database
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Risk of Infections Associated with the Use of Bispecific Antibodies in Multiple Myeloma: A Pooled Analysis
Maurizio Zangari
Winthrop Rockefeller Foundation
2 shared publications
In database
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Risk of Infections Associated with the Use of Bispecific Antibodies in Multiple Myeloma: A Pooled Analysis
John D. Shaughnessy
University of Arkansas for Medical Sciences
2 shared publications
In database
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Risk of Infections Associated with the Use of Bispecific Antibodies in Multiple Myeloma: A Pooled Analysis
Fenghuang Zhan
Winthrop Rockefeller Foundation
2 shared publications
In database
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Risk of Infections Associated with the Use of Bispecific Antibodies in Multiple Myeloma: A Pooled Analysis
Frits van Rhee
Winthrop Rockefeller Foundation
2 shared publications
In database
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Risk of Infections Associated with the Use of Bispecific Antibodies in Multiple Myeloma: A Pooled Analysis
Samer Al Hadidi
University of Arkansas for Medical Sciences
2 shared publications
In database
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Risk of Infections Associated with the Use of Bispecific Antibodies in Multiple Myeloma: A Pooled Analysis
Brad Fugere
Central Arkansas Veterans Healthcare System (US)
2 shared publications
- Abstract 4385: Unprecedented tumor: immune interaction–clinical and drug-development implications
- Weight loss (WL) as a predictive factor for immune oncology (IO).
Samuel L. Schach
University of Arkansas for Medical Sciences
2 shared publications
In database
- 512LBA (PB-512) LBA Posters: Off-the-Shelf Therapeutic Overactivation (TOA): A plea we can’t refuse!
- Abstract 3214: The duration of immune checkpoint inhibitors (ICI) in oncology: Longer is not better
Mazin Safar
University of Arkansas for Medical Sciences (US)
2 shared publications
- Tumor Response to Immune-Oncology Therapy Despite High-Dose Steroid Intervention in a Patient With Papillary Renal Cell Carcinoma and Immune-Related Myasthenia Gravis
- Ongoing Radiographic Response for Over 20 Months in Metastatic Cancer Without Continued Immune Checkpoint Inhibitor (ICI) Dosing
Ashton Ingold
University of Arkansas for Medical Sciences
2 shared publications
In database
- Exploring new frontiers in eosinophilic chronic rhinosinusitis
- Hospitalizations and Severity of Rhinovirus-Associated Asthma Exacerbations in Children During the Institution of Non-pharmaceutical Interventions
Dana Frederick
University of Arkansas for Medical Sciences
2 shared publications
In database
- Exploring new frontiers in eosinophilic chronic rhinosinusitis
- Hospitalizations and Severity of Rhinovirus-Associated Asthma Exacerbations in Children During the Institution of Non-pharmaceutical Interventions
Ahmad Mazin Safar
1 shared publication
- Abstract 4385: Unprecedented tumor: immune interaction–clinical and drug-development implications
Similar Researchers
Based on overlapping research topics
Naveen Yarlagadda
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Immune Response and Inflammation
Farah Mazahreh
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
SARS-CoV-2 and COVID-19 Research
Syed Mujtaba Ali Naqvi
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Immune Response and Inflammation
Trilok Shrivastava
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
SARS-CoV-2 and COVID-19 Research
Samer Al Hadidi
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Immune Response and Inflammation
Farah Mazahvreh
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Immune Response and Inflammation
Meta-analysis and systematic reviews